{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034822","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.276146+00:00","generated_at":"2026-05-16T20:13:44.239690+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track","bullets":["Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.","ADHD portfolio net revenue $13.2M; ex-rebate up 10% YoY on price increases and improved gross-to-nets.","Net income $2.0M ($0.21 basic EPS) vs $1.5M ($0.24) prior year; includes $3.8M derivative warrant gain.","Adjusted EBITDA $(0.6)M includes EXXUA launch investments; cash $32.6M at Sep 30.","EXXUA (gepirone) on track for commercial launch in Q4 2025; patent extended to Sep 2030; targeting $22B MDD market."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034822","json":"https://secwatch.observer/filing/0001437749-25-034822.json","markdown":"https://secwatch.observer/filing/0001437749-25-034822.md","text":"https://secwatch.observer/filing/0001437749-25-034822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/0001437749-25-034822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/aytu20250924_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:13:44.239690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}